...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pharmaceutical care. >Role of Iron in Hyperoxia-Induced Lung Injury: One Step Forward in
【24h】

Role of Iron in Hyperoxia-Induced Lung Injury: One Step Forward in

机译：铁在高氧血症引起的肺损伤中的作用：向前迈进了一步

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: An increased oxidative stress in patients under treatment with high concentrations of oxygen (hyperoxia) is considered to be one of the major mechanisms of lung injury. Between different mediators, transition metal ions especially iron, by generation of very reactive free radicals play an important role in oxidative stress process. Disruption of normal iron hemostasis has been reported in hyperoxic conditions. So we hypothesized that chelation of iron can reduce hyperoxia- induced lung injury.Methods: Mechanically ventilated patients, who received oxygen with FiO > 0.5 for at least 3 days, underwent bronchoscopy at baseline and 72 hours thereafter. Data from external control cases were collected prospectively to provide a comparative reference group.Iron and Iron-related proteins were measured in lavage fluid and plasma.Results: In 24 patients and in comparison with the results of previous study, Iron concentration decreased significantly in lavage fluid (P<0.001). Reduction of ferritin was not significant in lavage fluid (P: 0.7).Transferrin decreased significantly in plasma (P: 0.01). Acute Physiology And Chronic Health Evaluation (APACHE) II (P: 0.006) score decreased significantly after 7 days of follow-up. Conclusion: Deferasirox did not change Iron and Iron-related protein in hyperoxic condition and it just only could be considered along with other supportive measures for better toleration of oxygen therapy.
机译：背景：在接受高浓度氧气治疗（高氧血症）的患者中，氧化应激的增加被认为是肺部损伤的主要机制之一。在不同的介体之间，过渡金属离子（尤其是铁）通过产生非常活泼的自由基而在氧化应激过程中起重要作用。在高氧条件下有正常铁止血的报道。因此，我们假设铁的螯合可以减轻高氧血症引起的肺损伤。方法：机械通气的患者在FiO> 0.5的情况下接受氧气至少3天，在基线及此后72小时接受支气管镜检查。前瞻性收集外部对照病例的数据以提供一个比较参考组。在灌洗液和血浆中检测铁和铁相关蛋白。结果：24例患者与以前的研究结果相比，灌洗液中铁浓度显着降低液体（P <0.001）。灌洗液中铁蛋白的减少不显着（P：0.7），血浆中转铁蛋白显着降低（P：0.01）。随访7天后，急性生理和慢性健康评估（APACHE）II（P：0.006）得分显着下降。结论：Deferasirox在高氧条件下不会改变铁和铁相关蛋白，只能与其他支持措施一起考虑，以更好地耐受氧疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号